Advertisement

Chemical Cardiomyopathies: The Negative Effects of Medications and Nonprescribed Drugs on the Heart

  • Vincent M. Figueredo
    Correspondence
    Requests for reprints should be addressed to Vincent M. Figueredo, MD, Einstein Institute for Heart and Vascular Health, 5501 Old York Road, Levy 3232, Philadelphia, PA 19141
    Affiliations
    Einstein Institute for Heart and Vascular Health, Albert Einstein Medical Center, and Jefferson Medical College, Philadelphia, Pa
    Search for articles by this author

      Abstract

      The heart is a target of injury for many chemical compounds, both medically prescribed and not medically prescribed. Pathophysiologic mechanisms underlying the development of chemical-induced cardiomyopathies vary depending on the inciting agent, including direct toxic effects, neurohormonal activation, altered calcium homeostasis, and oxidative stress. Numerous chemicals and drugs are implicated in cardiomyopathy. This article discusses examples of medication and nonprescribed drug-induced cardiomyopathies and reviews their pathophysiologic mechanisms.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • 10th Congress of the International Society for Biomedical Research on Alcoholism
        Abstracts.
        Alcohol Clin Exp Res. 2000; 24 (Yokohama, Japan, 2-8 July 2000): 159A-229A
        • Gavazzi A.
        • De Maria R.
        • Parolini M.
        • Porcu M.
        Alcohol abuse and dilated cardiomyopathy in men.
        Am J Cardiol. 2000; 85: 1114-1118
        • Skotzko C.E.
        • Vrinceanu A.
        • Krueger L.
        • Freudenberger R.
        Alcohol use and congestive heart failure: incidence, importance, and approaches to improved history taking.
        Heart Fail Rev. 2009; 14: 51-55
        • Piano M.R.
        Alcoholic cardiomyopathy: incidence, clinical characteristics, and pathophysiology.
        Chest. 2002; 121: 1638-1650
        • Awtry E.H.
        • Philippides G.J.
        Alcoholic and cocaine-associated cardiomyopathies.
        Prog Cardiovasc Dis. 2010; 52: 289-299
        • Kesteloot H.
        • Roelandt J.
        • Willems J.
        • Claes J.H.
        • Joossens J.V.
        An enquiry into the role of cobalt in the heart disease of chronic beer drinkers.
        Circulation. 1968; 37: 854-864
        • Laonigro I.
        • Correale M.
        • Di Biase M.
        • Altomare E.
        Alcohol abuse and heart failure.
        Eur J Heart Fail. 2009; 11: 453-462
        • De Keulenaer G.W.
        • Brutsaert D.L.
        Dilated cardiomyopathy: changing pathophysiological concepts and mechanisms of dysfunction.
        J Card Surg. 1999; 14: 64-74
        • Fauchier L.
        • Babuty D.
        • Poret P.
        • et al.
        Comparison of long-term outcome of alcoholic and idiopathic dilated cardiomyopathy.
        Eur Heart J. 2000; 21: 306-314
        • Figueredo V.M.
        • Chang K.C.
        • Baker A.J.
        • Camacho S.A.
        Chronic alcohol-induced changes in cardiac contractility are not due to changes in the cytosolic Ca2+ transient.
        Am J Physiol. 1998; 275: H122-H130
        • Urbano-Marquez A.
        • Estruch R.
        • Navarro-Lopez F.
        • Grau J.M.
        • Mont L.
        • Rubin E.
        The effects of alcoholism on skeletal and cardiac muscle.
        N Engl J Med. 1989; 320: 409-415
      1. Report of the Dietary Guidelines Advisory Committee Dietary Guidelines for Americans, 1995.
        Nutr Rev. 1995; 53: 376-379
        • Francis G.S.
        • Johnson T.H.
        • Ziesche S.
        • Berg M.
        • Boosalis P.
        • Cohn J.N.
        Marked spontaneous improvement in ejection fraction in patients with congestive heart failure.
        Am J Med. 1990; 89: 303-307
        • Nicolas J.M.
        • Fernandez-Sola J.
        • Estruch R.
        • et al.
        The effect of controlled drinking in alcoholic cardiomyopathy.
        Ann Intern Med. 2002; 136: 192-200
      2. Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies.
        Br Heart J. 1980; 44: 672-673
        • Lazarevic A.M.
        • Nakatani S.
        • Neskovic A.N.
        • et al.
        Early changes in left ventricular function in chronic asymptomatic alcoholics: relation to the duration of heavy drinking.
        J Am Coll Cardiol. 2000; 35: 1599-1606
        • Kupari M.
        • Koskinen P.
        • Suokas A.
        Left ventricular size, mass and function in relation to the duration and quantity of heavy drinking in alcoholics.
        Am J Cardiol. 1991; 67: 274-279
        • George A.
        • Figueredo V.M.
        Alcohol and arrhythmias: a comprehensive review.
        J Cardiovasc Med (Hagerstown). 2010; 11: 221-228
        • Miyamae M.
        • Kaneda K.
        • Domae N.
        • Figueredo V.M.
        Cardioprotection by regular ethanol consumption: potential mechanisms and clinical application.
        Curr Drug Abuse Rev. 2010; 3: 39-48
        • Maraj S.
        • Figueredo V.M.
        • Lynn Morris D.
        Cocaine and the heart.
        Clin Cardiol. 2010; 33: 264-269
        • Felker G.M.
        • Hu W.
        • Hare J.M.
        • Hruban R.H.
        • Baughman K.L.
        • Kasper E.K.
        The spectrum of dilated cardiomyopathy.
        Medicine (Baltimore). 1999; 78: 270-283
        • Curry L.A.
        • Wagman D.F.
        Qualitative description of the prevalence and use of anabolic androgenic steroids by United States powerlifters.
        Percept Mot Skills. 1999; 88: 224-233
      3. American College of Sports Medicine position stand on the use of anabolic-androgenic steroids in sports.
        Med Sci Sports Exerc. 1987; 19: 534-539
        • De Piccoli B.
        • Giada F.
        • Benettin A.
        • Sartori F.
        • Piccolo E.
        Anabolic steroid use in body builders: an echocardiographic study of left ventricle morphology and function.
        Int J Sports Med. 1991; 12: 408-412
        • Pearson A.C.
        • Schiff M.
        • Mrosek D.
        • Labovitz A.J.
        • Williams G.A.
        Left ventricular diastolic function in weight lifters.
        Am J Cardiol. 1986; 58: 1254-1259
        • Ahlgrim C.
        • Guglin M.
        Anabolics and cardiomyopathy in a bodybuilder: case report and literature review.
        J Card Fail. 2009; 15: 496-500
        • Thilbin I.
        • Kristiansson M.
        • Rajs J.
        Anabolic androgenic steroids and behavioral patterns among violent offenders.
        J Forensic Psych. 1997; 8: 299-310
        • Crean A.M.
        • Pohl J.E.
        ‘Ally McBeal heart?'—drug induced cardiomyopathy in a young woman.
        Br J Clin Pharmacol. 2004; 58: 558-559
        • Samenuk D.
        • Link M.S.
        • Homoud M.K.
        • et al.
        Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine.
        Mayo Clin Proc. 2002; 77: 12-16
        • Haller C.A.
        • Benowitz N.L.
        Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids.
        N Engl J Med. 2000; 343: 1833-1838
        • Shenouda S.K.
        • Varner K.J.
        • Carvalho F.
        • Lucchesi P.A.
        Metabolites of MDMA induce oxidative stress and contractile dysfunction in adult rat left ventricular myocytes.
        Cardiovasc Toxicol. 2009; 9: 30-38
        • Mizia-Stec K.
        • Gasior Z.
        • Wojnicz R.
        • et al.
        Severe dilated cardiomyopathy as a consequence of Ecstasy intake.
        Cardiovasc Pathol. 2008; 17: 250-253
        • Shenouda S.K.
        • Lord K.C.
        • McIlwain E.
        • Lucchesi P.A.
        • Varner K.J.
        Ecstasy produces left ventricular dysfunction and oxidative stress in rats.
        Cardiovasc Res. 2008; 79: 662-670
        • Bolton J.L.
        • Trush M.A.
        • Penning T.M.
        • Dryhurst G.
        • Monks T.J.
        Role of quinones in toxicology.
        Chem Res Toxicol. 2000; 13: 135-160
        • Swain S.M.
        • Whaley F.S.
        • Ewer M.S.
        Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.
        Cancer. 2003; 97: 2869-2879
        • Lipshultz S.E.
        • Lipsitz S.R.
        • Mone S.M.
        • et al.
        Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.
        N Engl J Med. 1995; 332: 1738-1743
        • Steinherz L.J.
        • Steinherz P.G.
        • Tan C.T.
        • Heller G.
        • Murphy M.L.
        Cardiac toxicity 4 to 20 years after completing anthracycline therapy.
        JAMA. 1991; 266: 1672-1677
        • Zucchi R.
        • Danesi R.
        Cardiac toxicity of antineoplastic anthracyclines.
        Curr Med Chem Anticancer Agents. 2003; 3: 151-171
        • Takemura G.
        • Fujiwara H.
        Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management.
        Prog Cardiovasc Dis. 2007; 49: 330-352
        • Yeh E.T.
        • Tong A.T.
        • Lenihan D.J.
        • et al.
        Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management.
        Circulation. 2004; 109: 3122-3131
        • Chu T.F.
        • Rupnick M.A.
        • Kerkela R.
        • et al.
        Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.
        Lancet. 2007; 370: 2011-2019
        • Jones L.W.
        • Haykowsky M.J.
        • Swartz J.J.
        • Douglas P.S.
        • Mackey J.R.
        Early breast cancer therapy and cardiovascular injury.
        J Am Coll Cardiol. 2007; 50: 1435-1441
        • August C.
        • Holzhausen H.J.
        • Schmoldt A.
        • Pompecki R.
        • Schroder S.
        Histological and ultrastructural findings in chloroquine-induced cardiomyopathy.
        J Mol Med. 1995; 73: 73-77
        • Rostagno C.
        • Domenichetti S.
        • Pastorelli F.
        • Gensini G.F.
        Clozapine associated cardiomyopathy: a cluster of 3 cases.
        Intern Emerg Med. 2010 Oct 8; ([Epub ahead of print])
        • Ronaldson K.J.
        • Taylor A.J.
        • Fitzgerald P.B.
        • Topliss D.J.
        • Elsik M.
        • McNeil J.J.
        Diagnostic characteristics of clozapine-induced myocarditis identified by an analysis of 38 cases and 47 controls.
        J Clin Psychiatry. 2010; 71: 976-981
        • Makhoul B.
        • Hochberg I.
        • Rispler S.
        • Azzam Z.S.
        Dilated cardiomyopathy: an unusual complication of clozapine therapy.
        Nat Clin Pract Cardiovasc Med. 2008; 5: 566-570
        • Nymark T.B.
        • Hovland A.
        • Bjornstad H.
        • Nielsen E.W.
        A young man with acute dilated cardiomyopathy associated with methylphenidate.
        Vasc Health Risk Manag. 2008; 4: 477-479
        • Tollofsrud C.
        • Hoel T.
        A young man with acute dilated cardiomyopathy.
        Todsskr Nor Laegeforen. 2006; 126: 1338-1339
        • Nissen S.E.
        ADHD drugs and cardiovascular risk.
        N Engl J Med. 2006; 354: 1445-1448
        • Henderson T.A.
        • Fischer V.W.
        Effects of methylphenidate (Ritalin) on mammalian myocardial ultrastructure.
        Am J Cardiovasc Pathol. 1995; 5: 68-78

      Linked Article